Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS – Free Report) from a hold rating to a buy rating in a report released on Saturday morning,Wall Street Zen reports.
A number of other analysts have also commented on the company. Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 3rd. Weiss Ratings raised Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. reduced their price objective on Grifols from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, October 26th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $9.00.
View Our Latest Analysis on GRFS
Grifols Stock Performance
Grifols stock opened at $8.73 on Friday. Grifols has a 52 week low of $6.96 and a 52 week high of $9.77. The company’s 50 day moving average price is $7.76 and its two-hundred day moving average price is $7.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.33 and a quick ratio of 0.82.
Grifols Announces Dividend
The business also recently declared a dividend, which will be paid on Monday, January 11th. Investors of record on Thursday, December 3rd will be issued a $0.1686 dividend. This represents a dividend yield of 385.0%. The ex-dividend date of this dividend is Thursday, December 3rd.
Hedge Funds Weigh In On Grifols
Several institutional investors have recently bought and sold shares of GRFS. Flat Footed LLC boosted its position in shares of Grifols by 26.5% during the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after acquiring an additional 287,867 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Grifols by 9.8% during the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after purchasing an additional 109,612 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Grifols by 15.4% during the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after purchasing an additional 104,850 shares in the last quarter. Quantinno Capital Management LP increased its position in shares of Grifols by 42.0% in the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock worth $2,829,000 after purchasing an additional 104,418 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Grifols by 13.8% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock worth $4,193,000 after purchasing an additional 72,037 shares during the last quarter.
Grifols Company Profile
Grifols is a global healthcare company headquartered in Barcelona, Spain, focused on developing and producing plasma-derived medicines and other healthcare products. Founded in 1909, the company has expanded from its origins in laboratory services into a business spanning plasma collection, biopharmaceuticals, diagnostics and hospital solutions. Its biopharmaceutical business collects and processes human plasma to make medicines, including immunoglobulins, albumin and coagulation factors. Grifols also supplies diagnostic products and services for transfusion medicine and offers products used in hospitals and clinical laboratories.
Further Reading
- Five stocks we like better than Grifols
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
